Major UK Trial Undermines Promise of Galleri Multi-Cancer Blood Test
TL;DR Summary
In a large UK trial of 142,000 adults over three years, Grail's Galleri multi-cancer blood test did not reduce late-stage cancers (stages 3–4), though researchers noted a secondary signal of fewer Stage 4 cancers; the test remains FDA-unapproved, is sold with limited insurer coverage, and Medicare coverage remains under legislative review.
- Grail’s Cancer Detection Test Fails in Major Study The New York Times
- Grail stock craters as key NHS-Galleri cancer blood test trial fails to hit primary endpoint Fierce Biotech
- Grail shares plummet after UK study raises doubts over cancer test's prospects Reuters
- Grail Stock Tanks After Cancer-Screening Study The Wall Street Journal
- Key study of Grail’s cancer detection test fails in setback for company statnews.com
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
741 → 51 words
Want the full story? Read the original article
Read on The New York Times